An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors.
Clin Epigenetics
; 13(1): 224, 2021 12 17.
Article
em En
| MEDLINE
| ID: mdl-34920739
ABSTRACT
Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied. We performed a post-hoc analysis of a randomized controlled trial among overweight/obese breast cancer survivors (N = 192) assigned to metformin, placebo, weight loss with metformin, or weight loss with placebo interventions for 6 months. Epigenetic age was correlated with chronological age (r = 0.20-0.86; P < 0.005). However, no significant epigenetic aging associations were observed by intervention arms. Consistent with published reports in non-cancer patients, 6 months of metformin therapy may be inadequate to observe expected epigenetic age deceleration. Longer duration studies are needed to better characterize these relationships.Trial Registration Registry Name ClincialTrials.Gov.Registration Number NCT01302379.Date of Registration February 2011.URL https//clinicaltrials.gov/ct2/show/NCT01302379.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Envelhecimento
/
Sobrepeso
/
Metformina
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
Limite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Clin Epigenetics
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos